Quality assessment | No. of patients | Hazard Ratios (95% CI) | Quality | Importance | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | TKI-induced hypertension | Control | |||
Progression-free survival (follow-up median 5.6–43.2 years; measured with: follow-up) | |||||||||||
20 | observational studies | no serious risk of bias | serious1 | no serious indirectness | no serious imprecision | reporting bias2 | 3021 | 1327 | 0.59 (0.48–0.71) | Very low | Critical |
Overall survival (follow-up median 5.2–61.8 months; measured with: follow-up) | |||||||||||
17 | observational studies | no serious risk of bias | serious1 | no serious indirectness | no serious imprecision | reporting bias3 | 2313 | 1804 | 0.57 (0.45–0.70) | Very low | Critical |